Systemic immune-inflammation index and neutrophil-to-lymphocyte ratio predict treatment responses in elderly patients with profound sudden deafness

全身免疫炎症指数和中性粒细胞与淋巴细胞比值可预测老年重度突发性耳聋患者的治疗反应

阅读:1

Abstract

The aim of the present study was to evaluate the potential role of the neutrophil-to-lymphocyte ratio (NLR) and the systemic immune-inflammation index (SII) in predicting hearing recovery among elderly patients with profound sudden sensorineural hearing loss (SSNHL) following steroid treatment. The present retrospective study analyzed data from 186 elderly patients with profound SSNHL. Clinical characteristics and laboratory parameters were assessed to identify independent predictors of hearing outcomes using logistic regression and receiver operating characteristic (ROC) analyses. Baseline characteristics were generally comparable across groups; however, NLR, SII, total bilirubin (TBIL) and C-reactive protein (CRP) were significantly elevated in the non-recovery group (P<0.001). Multivariate logistic regression analysis further demonstrated that elevated NLR and SII were independent risk factors for poor hearing recovery; notably, increased CRP and TBIL levels were also independently associated with a higher likelihood of no recovery. ROC analysis demonstrated that both the NLR [area under the curve (AUC)=0.809] and SII (AUC=0.862) possessed a strong discriminatory ability for identifying non-recovery. In an exploratory analysis, the combined use of CRP, TBIL, SII and NLR achieved the highest predictive performance for distinguishing no recovery from complete recovery, with an AUC of 0.951 (95% CI, 0.907-0.996; P<0.001). Overall, elevated NLR and SII were independent predictors of poor hearing recovery in elderly patients with profound SSNHL. These readily available inflammatory markers may serve as useful prognostic tools for outcome stratification in clinical practice.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。